Pulmonary fibrosis inhibited by pentraxin-2/SAP in research study
Promedior, Inc., a clinical stage biotechnology company developing novel therapies to treat fibrotic and inflammatory diseases, announced today the publication of collaborative research in the International Journal of Biochemistry and Cell Biology entitled, "TGF-beta driven lung fibrosis is macrophage dependent and blocked by Serum amyloid P." The research showed that human Pentraxin-2 (PTX-2), also called human Serum amyloid P (SAP), potently inhibits all undesirable pro-fibrotic pathologies driven by TGFβ1 and represents a novel therapeutic approach for the treatment of diseases that involve lung fibrosis, including idiopathic pulmonary fibrosis (IPF). This research validates that PTX-2/SAP can have therapeutic effects even in conditions driven by TGFβ1 growth factor, and builds on the body of research showing the unique role of PTX-2/SAP in activating the body's natural ability to resolve tissue damage in disease processes that cause fibrosis and inflammation.
